N-[3-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide | 1580452-62-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-[3-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide
• 英文别名: N-[3-[3-(4-pyridyl)imidazo [1,2-b]pyridazin-6-yl]phenyl] methane-sulfonamide；N-[3-(3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-yl)phenyl]methanesulfonamide
• CAS: 1580452-62-5
• 化学式: C₁₈H₁₅N₅O₂S
• 分子量: 365.415
• InChiKey: AHJLSFJGPNXLKP-UHFFFAOYSA-N

物化性质

• 熔点：
  253 °C
• 密度：
  1.42±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  97.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-氯-3-碘咪唑并[1,2-B]哒嗪 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N-[3-[3-(4-pyridyl)imidazo[1,2-b]pyridazin-6-yl]phenyl]methanesulfonamide
  参考文献：
  名称：

  Medicinal Chemistry Optimization of Antiplasmodial Imidazopyridazine Hits from High Throughput Screening of a SoftFocus Kinase Library: Part 1

  摘要：

  A novel class of imidazopyridazines identified from whole cell screening of a SoftFocus kinase library was synthesized and evaluated for antiplasmodial activity against K1 (multidrug resistant strain) and NF54 (sensitive strain). Structure-activity relationship studies led to the identification of highly potent compounds against both strains. Compound 35 was highly active (IC50: K1 = 6.3 nM, NF54 = 7.3 nM) and comparable in potency to artesunate, and 35 exhibited 98% activity in the in vivo P. berghei mouse model (4-day test by Peters) at 4 × 50 mg/kg po. Compound 35 was also assessed against P. falciparum in the in vivo SCID mouse model where the efficacy was found to be more consistent with the in vitro activity. Furthermore, 35 displayed high (78%) rat oral bioavailability with good oral exposure and plasma half-life. Mice exposure at the same dose was 10-fold lower than in rat, suggesting lower oral absorption and/or higher metabolic clearance in mice.

  DOI：

  10.1021/jm500098s

文献信息

• Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2818471A1

  公开（公告）日：2014-12-31

  The present invention relates to compounds assumed to be capable of modulating the activity of the proteins ScyI1 and Grk5, thereby regulating the expression and/or release of insulin as well as to pharmaceutical compositions containing such compounds and the use thereof especially for the treatment of a metabolic disease such as diabetes, obesity and impaired adipogenesis.

  本发明涉及假设能够调节蛋白质ScyI1和Grk5活性的化合物，从而调节胰岛素的表达和/或释放，以及包含此类化合物的药物组合物及其用途，特别是用于治疗糖尿病、肥胖和脂肪生成受损等代谢性疾病。
• [EN] SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE LA LÉMUR TYROSINE KINASE 3
  申请人：UNIV SUSSEX

  公开号：WO2022053838A1

  公开（公告）日：2022-03-17

  The present invention relates to compounds of formula (I) and compositions comprising the same. The compounds and compositions may be used treat, prevent or ameliorate diseases treatable by inhibition of the Lemur tyrosine kinase 3 (LMTK3), such as cancer.

  本发明涉及公式（I）的化合物和包含该化合物的组合物。这些化合物和组合物可用于治疗、预防或改善通过抑制Lemur酪氨酸激酶3（LMTK3）可治疗的疾病，如癌症。
• Methods, compositions, and uses of novel Fyn kinase inhibitors
  申请人：Lau Warren C.

  公开号：US10688093B2

  公开（公告）日：2020-06-23

  The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.

  本发明提供了使用 5-3-吡啶-2-胺、6-3-咪唑并[1,2-a]吡嗪、6-3-咪唑并[1,2-b]哒嗪、N-(5-咪唑并[2,1-b][1,3,4]噻二唑-2-基)胺、4-3-1H-吡唑并[3、4-b]吡啶和 N-(3-咪唑并[1,2-b]哒嗪-6-基)胺化合物，以及使用此类化合物治疗、预防、抑制或改善与 Fyn 激酶相关的疾病和病症的方法。
• METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS
  申请人：Lau, Warren C.

  公开号：EP3347462A1

  公开（公告）日：2018-07-18
• KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

  公开号：US20150079108A1

  公开（公告）日：2015-03-19

  The present invention is related to compound capable of modulating the activity and/or expression of the protein kinase GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.